A Radium-223 microgenerator from cyclotron-produced trace Actinium-227

Citations of this article
Mendeley users who have this article in their library.


The alpha particle emitter Radium-223 dichloride (223RaCl2) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of 223Ra is limited and expensive. We have engineered a 223Ra microgenerator using traces of 227Ac previously generated from cyclotron-produced 225Ac. Radiochemically pure 223RaCl2 was made, characterized, evaluated in vivo, and the source was recovered in high yield for regeneration of the microgenerator.




Abou, D. S., Pickett, J., Mattson, J. E., & Thorek, D. L. J. (2017). A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. Applied Radiation and Isotopes, 119, 36–42. https://doi.org/10.1016/j.apradiso.2016.10.015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free